Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
NCT Number: NCT05491278
The purpose of this study is to evaluate the efficacy and safety of fospropofol disodium for injection compared to propofol for sedation in mechanically ventilated ICU patients.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 2
Wuhan, China
This is a randomized, open-label, small sample study using fospropofol disodium and propofol for sedation in mechanically ventilated ICU patients. Subjects are randomized to different treatment groups (including 1 for fospropofol disodium and 1 for propofol). Remifentanil is co-administered with fospropofol or propofol. Efficacy and safety profiles of fospropofol disodium are to be evaluated.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Fospropofol disodium for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
Other names: Remifentanil
Propofol for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
Other names: Remifentanil
Time frame: Within 7 days of the study began
Proportion of RASS assessment time points for subjects meeting target sedation levels among all RASS assessment time points during study drug administration without rescue sedation.
Time frame: Within 7 days of the study began
The time without invasive ventilation within 7 days of the study began
Time frame: Within 7 days of the study began
The proportion of participants who experienced successful extubation within 7 days of the study began
Time frame: Within 7 days of the study began
Incidence of all extubation not planned by the attending physician
Time frame: During ICU stay
Delirium as a percentage of all evaluable mental patients in the ICU
Time frame: Within 28 days of the study began
The time of survival outside of ICU within 7 days of the study began
Time frame: Within 28 days of the study began
After follow-up, the fatality rates of all enrolled patients (including those still in ICU, transferred out and discharge) within 28 days of the study began
Time frame: Within 7 days of the study began
Percentage of time the trial drug was discontinued due to any adverse event suspected to be related to the trial drug
Xiaobo Yang, MD
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04612348
Critical Illness, Disease Attributes
Columbus, Ohio, United States
View Trial DetailsNCT03195127
Chronic Disease, Critical Illness
Baltimore, Maryland, United States
View Trial DetailsNCT07020637
Critical Illness, Disease Attributes
Las Vegas, Nevada, United States
View Trial DetailsNCT07579728
Critical Illness, Disease Attributes
Istanbul, Turkey (Türkiye)
View Trial Details